Pyrrolopyrimidine crystal for preparing JAK inhibitor
US10626118B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 15, 2017 |
| Grant date | Apr 21, 2020 |
| Priority date | — |
| Expiry date | Jun 15, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07B2200/13
- WIPO fieldChemical engineering
- WIPO sectorChemistry
Abstract
The present application relates to the field of pharmaceutical chemistry. The application specifically relates to a crystal form A and crystal form B of a pyrrolopyrimidine (formula I) for preparing a JAK inhibitor. The application further relates to a method for preparing the crystal form A and crystal form B, a crystalline composition comprising the crystal form A or crystal form B, a pharmaceutical composition comprising the crystal form A, crystal form B, or crystalline composition, and a pharmaceutical application of the pharmaceutical composition, the crystal form A, and the crystal form B. The crystal form A and crystal form B of the application has the advantages of high purity, high crystallinity, and good stability.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.